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Abstract
Hydrogen peroxide is a common antiseptic and disinfectant that is effective 
against both enveloped and non-enveloped viruses, and it is sometimes used as a 
fumigant to achieve disinfection of indoor spaces. While it is effective as a fumi-
gant, it cannot be used continuously, allowing for possible recontamination of the 
treated spaces between applications. A novel method of hydrogen peroxide applica-
tion, termed “Dry Hydrogen Peroxide” (DHP™), generates molecules of hydrogen 
peroxide in a true gas state at concentrations low enough to be used continuously 
within spaces occupied by humans. This chapter explores the efficacy of DHP 
against a variety of viruses, both enveloped and non-enveloped. On surfaces, 
DHP achieved a ≥ 99.8% reduction (≥2.62 log10 inactivation) of infectious H1N1 
influenza A (enveloped) compared to the control condition within 1 hour, and it 
achieved a 99.8% reduction (2.62 log10 inactivation) of infectious feline calicivirus 
(non-enveloped) compared to the control condition within 6 hours. DHP also 
achieved a 99.8% reduction 2.62 log10 inactivation) of airborne MS2 bacteriophage 
(non-enveloped) within 1 hour in comparison to the control condition. These 
inactivation efficacy results, combined with results from recent clinical studies, 
indicate that DHP represents an effective adjunct technology that can mitigate viral 
load between intermittent applications of other types of disinfectants.
Keywords: viral inactivation, dry hydrogen peroxide, disinfectant, hydroxyl radical, 
biocidal action
1. Introduction
Since the late 19th century, hydrogen peroxide (H2O2) has been used as a dis-
infectant and antiseptic due to its potent antimicrobial properties against a wide 
range of pathogens [1]. Hydrogen peroxide attacks the essential external structures 
of pathogens (i.e. cell walls, viral envelopes, etc.) via a simple oxidation reaction, 
thereby weakening the pathogen’s physical structure until it ultimately lyses from its 
own osmotic pressure [2–4]. Most commonly, H2O2 is used as a liquid antiseptic and 
disinfectant, but solutions of H2O2 are also vaporized and dispersed as a method of 
disinfection of indoor spaces. This process, however, requires the complete evacuation 
of personnel from the treated spaces, both during and for some time after the treat-
ment, to protect human occupants from the toxic effects of the highly concentrated 
droplets [5, 6]. Symptoms of overexposure to H2O2 include irritation of the eyes, nose, 
throat, skin, and/or lungs, and concentrations over 75 parts per million (ppm) are con-
sidered “immediately dangerous to life or health” in humans [7, 8]. Droplets of vapor-
ized hydrogen peroxide, depending on the generator, may contain concentrations 
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of approximately 400 ppm [9], therefore, while vaporized hydrogen peroxide is 
extremely effective as a sterilant, its potential for use in continuously occupied spaces 
is limited by its potency and potential toxicity to human occupants [10, 11].
Hydrogen peroxide is also an essential component of the human respiratory 
system, with human lungs maintaining an equilibrium concentration between 10−6 
and 10−4 M via the lactoperoxidase system of enzymes [12]. Two enzymes within 
this system, known as the Duox compound, constantly produce hydrogen peroxide, 
while the third enzyme, lactoperoxidase, converts that hydrogen peroxide into 
an even stronger oxidizing agent, the hypothiocyanite ion (OSCN−) [12, 13]. This 
enzymatic system allows the human body to tolerate low levels of hydrogen perox-
ide exposure without experiencing irritation or damage.
Recently, a new method of hydrogen peroxide generation and delivery termed Dry 
Hydrogen Peroxide (DHP™) was developed, with the goal of enabling safe continuous 
microbial inactivation to occur in occupied indoor spaces either when installed within 
an existing HVAC system or as a stand-alone device (Figures 1 and 2) [14]. DHP is 
produced by devices that include a 363 nm wavelength ultraviolet A (UV-A) bulb, 
which activates a proprietary photocatalyst that has been applied to a two-dimensional 
framed polyester mesh, referred to as a “sail”. Photons of UV-A radiation from the bulb 
excite electrons in the catalyst, promoting them to a higher energy state. This creates a 
positively charged “electron hole” in the valence band in the catalyst atoms, creating an 
active site. When ambient humidity (H2O) is adsorbed into these active sites, an elec-
tron is scavenged from the water molecule. This causes a subsequent release of a proton 
(H+) by the water molecule, and the resulting structure is a hydroxyl radical (OH˙). 
The catalyst now has a free electron, a proton (H+), and a hydroxyl radical available to 
perform oxidation reactions. Under normal circumstances, these three components 
simply combine to produce a water molecule in the gas phase. DHP technology, 
however, uses a proprietary plasma separation process to isolate hydroxyl radicals from 
the subatomic particles. This separation of the plasma allows for the hydroxyl radicals 
to combine and form stable molecules of hydrogen peroxide in a pure gas state (DHP), 
which are then dispersed throughout the space being treated. The subatomic particles 
that remain on the catalyst are then scavenged by ambient diatomic oxygen (O2), 
forming more molecules of DHP by means of reduction. The concentrations of DHP 
that are produced through this process are well below the OSHA safety limit of 1 ppm, 
allowing the lactoperoxidase system to easily maintain the equilibrium concentration 
of hydrogen peroxide to the level naturally present in the lungs [12, 13]. Additionally, 
Figure 1. 
In-line Dry Hydrogen peroxide (DHP) device intended for use in an HVAC system.
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it has been confirmed that DHP devices produced by the patent holder do not 
produce ozone, according to Underwriter’s Laboratories (UL) Standards 867 and 
2998 [15, 16]. A recent study performed by Ramirez et al. reported no incidence of 
symptoms associated with hydrogen peroxide overexposure in pediatric oncology 
patients who were continuously exposed to DHP during their stay in a Pediatric 
Intensive Care Unit (PICU) [17].
Due to the novelty and mechanism of generation of DHP, this disinfection 
system is often confused with older technologies, such as vaporized hydrogen 
peroxide, bipolar ionization, and photocatalytic oxidation, though it is distinct 
from each of those technologies.
2. Dry hydrogen peroxide and vaporized hydrogen peroxide
While DHP and vaporized hydrogen peroxide both utilize hydrogen peroxide 
to reduce infectious pathogen burdens in a treated indoor space, there are several 
notable differences between the two technologies. The most apparent difference 
between DHP and vaporized hydrogen peroxide is that DHP is a true gas composed 
of individual molecules exhibiting near ideal gas behavior [18], whereas VHP is an 
aerosol of highly concentrated aqueous droplets. As a result, vaporized hydrogen 
peroxide effectively sterilizes a room, but it also may lead to aerosol H2O2 concentra-
tions which exceed the safety limits for human exposure. Vaporized hydrogen perox-
ide may only be used in vacated areas. Other precautionary measures, such as sealing 
doors, windows, and HVAC systems, must be taken before use as well, in order to 
prevent unintended dissemination of H2O2 to adjacent spaces [5, 6, 9–11]. Further, 
in aqueous form, hydrogen peroxide forms a weak acid which is corrosive to some 
materials, equipment, and furnishings. Dry Hydrogen Peroxide, on the other hand, 
is much less concentrated, and does not cause such material compatibility issues. Dry 
Hydrogen Peroxide can be applied for an unlimited time of exposure and can be used 
in spaces occupied by humans. Dry Hydrogen Peroxide therefore represents a highly 
effective adjunct to the intermittent usage of harsher disinfectants.
2.1 Dry hydrogen peroxide and bipolar ionization
Bipolar ionization creates a plasma consisting of positive ions, negative ions, 
and free radicals, with the intention of releasing them into a space. This plasma can 
be generated in multiple ways, but the two primary types of bipolar ionization are 
Figure 2. 
Stand-alone Dry Hydrogen Peroxide (DHP) device.
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corona discharge and needlepoint. Both types of bipolar ionization utilize sets of 
oppositely charged electrodes to ionize ambient humidity and oxygen as the indoor 
air passes through the device. Corona discharge bipolar ionization is rarely utilized 
currently, due to the potential for generation of ozone; accordingly, most manufac-
turers have switched to needlepoint ionization [19]. Manufacturers of needlepoint 
bipolar ionization (NPBI) claim that the electrodes used in the devices produce 
an electric field with a voltage below 12 eV to eliminate the potential for ozone 
generation [20]. Dry Hydrogen Peroxide and bipolar ionization each utilize ambient 
humidity and oxygen in their generation processes and continuously disperse their 
products throughout treated spaces; however, DHP is produced as stable H2O2 mol-
ecules, while bipolar ions are an unstable plasma. Additionally, neutrally charged 
H2O2 generated from DHP can travel long distances, whereas the oppositely charged 
ions created by bipolar ionization may rapidly recombine, diminishing the effective 
concentration as distance from the device increases [21, 22].
2.1 Dry hydrogen peroxide and photocatalytic oxidation
Both DHP and Photocatalytic Oxidation (PCO) technologies utilize photocatal-
ysis during their respective processes, however DHP devices are not PCO devices 
[18, 23]. DHP technology uses a plasma-separation process to specifically produce 
free H2O2. Photocatalytic Oxidation technology, however, rapidly consumes any 
H2O2 that may form in the plasma, because H2O2 has a highly positive reduction 
potential (0.71 eV) and will be immediately reduced to water by subatomic par-
ticles in the plasma [24]. Photocatalytic Oxidation devices rely on a dense internal 
plasma zone within the device, but the microbicidal properties of the plasma only 
affect airborne microbes that circulate through the device, unless the device also 
produces ozone, which would impact microbes outside of the device.
2.2 Efficacy of DHP for inactivating viruses
Hydrogen peroxide’s biocidal action against viruses relies on the oxidation of 
essential biomolecules that compose the external structures of the virus (i.e. lipid 
envelope, protein capsid, etc.) [2–4]. Both enveloped and non-enveloped viruses 
are susceptible to this mechanism, even though non-enveloped viruses are decid-
edly less susceptible [25]. A recent study indicated that DHP effectively reduced 
infectious burden of the enveloped coronavirus SARS-CoV-2 on surfaces in a 
laboratory setting, achieving an estimated 98.7% (1.94 log10) reduction compared 
to the corresponding control condition after 120 minutes in a simulated room 
environment [26]. Dry Hydrogen Peroxide was also associated with significant 
surface reductions in bacteria in two separate studies conducted in active hospital 
patient rooms [17, 27]. While these studies address DHP’s efficacy against bacteria 
and enveloped viruses on surfaces, there have not yet appeared in the literature 
peer-reviewed reports detailing the efficacy of DHP against non-enveloped viruses 
or airborne enveloped viruses. The following sections will detail three previously 
unpublished laboratory trials that investigated DHP’s potential for inactivating 
airborne viruses or viruses dried on surfaces.
2.3 Efficacy of DHP for inactivating influenza A H1N1
H1N1 is a strain of influenza A (family Orthomyxoviridae) that was responsible 
for a 2009 pandemic declared by the World Health Organization (WHO). Like 
SARS-CoV-2, H1N1 is an enveloped virus, and it has been known to remain infec-
tious on non-porous surfaces, such as glass and stainless steel, for 24–48 hours 
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[28, 29]. A DHP device was tested against titers of H1N1, with a starting TCID50 of 
6.05 log10, in a laboratory biosafety hood to determine if DHP effectively inacti-
vated the virus in comparison to the control condition after 120 minutes exposure 
(Tables 1 and 2).
Aliquots of diluted stock H1N1 were used to inoculate 1″ × 1″ squares on the 
center of 1″ × 3″ glass slides that had previously been sterilized and autoclaved. 
The slides were then placed into plastic Petri dishes. Ten slides, in total, were 
prepared in this way, with duplicates for each timepoint: Time Zero, T = 60 minutes 
Virus Control, T = 120 minutes Virus Control, T = 60 minutes Virus Test Carrier, 
T = 120 minutes Virus Test Carrier. Once inoculated with virus, the slides were 
allowed to dry for 25 minutes at 24°C and 36% relative humidity. The dried carriers 
were placed in their respective laboratory hoods, one of which was currently being 
treated with a DHP device that had been operating for 12 hours to precondition the 
space. The Time Zero samples were immediately collected and eluted with 2 mL of 
Influenza Infection Medium (EMEM supplemented with 0.125% w/v bovine serum 
albumin +1 μg/mL TPCK-trypsin + antibiotics). Serial dilutions were then per-
formed to the 10−5 dilution and plated in quadruplicate onto MDCK (dog kidney) 
monolayers. At the designated timepoints, the T = 60 and the T = 120 samples were 
harvested and enumerated in an identical fashion to the Time Zero samples. The 
assay trays were then incubated at 35°C on an orbital rotator (60 rotations/minute) 
for 60 minutes. Once the virus-host cell adsorption had completed, the trays were 
removed from incubation, and 1.0 mL of the Influenza Infection Medium was 
pipetted into each well of the assay plate for each of the samples. The MDBK wells 
were then incubated for 7 days. All titers were determined using the Spearman-
Kärber method [30].
After the incubation was complete, the wells were scored for viral cytopathic 
effect (CPE), and the Tissue Culture Infectivity Dose at the 50% Endpoint Dilution 
(TCID50) was calculated for each pair of samples (Table 2). In comparison to the 
control, the DHP-treated samples yielded a ≥ 2.62 log10 reduction in virus titer at 
60 minutes and a ≥ 1.87 log10 reduction at 120 minutes. The log10 reduction in titer 
observed at 60 minutes corresponds to a percent reduction of ≥99.8%, compared to 
the control condition (Table 2) [31].
Virus Strain Cell line Description Culture medium
Influenza A 
(H1N1)b
A/PR/8/34 MDCK Canine 
Kidney
EMEM +0.125% bovine serum 
albumin w/v + 1 μg/mL TPCK-
trypsin + antibiotics











15597-B1 E. coli 15597 Gram 
Negative 
Bacteria
50% Tryptic Soy Agar
aAbbreviations used: ATCC, American Type Culture Collection; CRFK, Crandel-Reese Feline Kidney; EMEM, 
Eagle’s Minimum Essential Media; MDCK, Madin-Darby Canine Kidney; MEM, Minimum Essential Media.
bTesting performed at Antimicrobial Test Laboratories, Round Rock, Texas, USA.
cTesting performed at ATS Labs, Eagan, MN, USA.
dTesting performed at Microchem Laboratory, Round Rock, TX, USA.
Table 1. 
Summary of viruses and detector cells used in these efficacy studiesa.
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2.5 Efficacy of DHP for inactivating feline calicivirus
Feline calicivirus (FeCV) is a non-enveloped, single-stranded RNA virus (family 
Caliciviridae) that is often used as a surrogate in laboratory testing to simulate 
human norovirus, a major cause of gastrointestinal hospital-acquired infections 
(HAIs) [32, 33]. On non-porous surfaces, FeCV has been found to remain viable for 
12–72 hours [34]. The efficacy of a prototype DHP device was tested against titers 
of FeCV, with a starting titer of 6.6 log10 TCID50/mL, over the course of 24 hours 
(Tables 1 and 3).
Aliquots of FeCV (ATCC VR-782) were inoculated onto glass slides with an 
accompanying organic soil load of ≤1% fetal bovine serum (FBS) to simulate con-
tamination in a physiological matrix. The original titer of the input virus control was 
approximately 8.0 log10/mL, but after being allowed to dry on the carriers, the FeCV 
titer had decreased to an average of 6.6 log10/ml. For both the control and treatment 
groups, duplicate samples were collected at each timepoint (Time zero, T = 2 hours, 
T = 6 hours, T = 24 hours). After drying of the virus onto the slides was complete, the 
carriers were placed in their respective biosafety laboratory hoods, and the DHP device 
was activated in the hood containing the treatment group of samples. Temperature and 
humidity levels remained between 21 and 24°C and 36–39%, respectively, through-
out the duration of the experiment. The test carriers were retrieved and scraped to 
resuspend the contents at the designated timepoints. Each sample’s contents were 
transferred to a sterile tube and then serially diluted in the test medium (MEM supple-
mented with inactivated FBS, 100 units/mL penicillin, gentamicin, and 2.5 μg/mL  
amphotericin B). Once diluted, a cell-based infectivity assay involving Crandel Reese 
feline kidney (CRFK) cells was used to determine infectious titer.
The average titer (TCID50/mL) for each pair of samples was then calculated 
(Table 3). DHP-treatment resulted in FeCV inactivation (1.5 log10 after 2 hours, 
Feline calicivirus titer (TCID50/mL)
Time zero T = 2 hr T = 6 hr T = 24 hr
Control 6.6 5.8 5.1 3.4
DHP-Treated 6.6 4.3 2.3 ≤0.6
Log10 Inactivation* 1.5 2.8 ≥2.8
Percent reduction* 96.8% 99.8% ≥99.8%
*Compared to Control.
Table 3. 
Inactivation of feline calicivirus over time by exposure to Dry Hydrogen Peroxide (DHP).
Influenza virus titer (TCID50/mL)
Time zero T = 60 min T = 120 min
Control 6.05 4.80 3.80
DHP-Treated 6.05 ≤2.18 ≤1.93
Log10 Inactivation* ≥2.62 ≥1.87
Percent reduction* ≥99.8% ≥98.6%
*Compared to Control.
Table 2. 
Inactivation of influenza virus H1N1 over time by exposure to Dry Hydrogen Peroxide (DHP).
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and 2.8 log10 reduction after 6 hours of exposure time). The 2-hour and 6-hour log10 
reductions in infectious titer correspond to 96.8% and 99.8% inactivation, respec-
tively, in comparison to the control condition (Table 3) [35].
2.6 Efficacy of DHP for inactivating MS2 bacteriophage
MS2 is a single-stranded non-enveloped RNA bacteriophage that often infects 
Escherichia coli (E. coli), and has been used as a surrogate for human norovirus 
and other non-enveloped viruses. MS2 bacteriophage has been shown to survive 
on non-porous surfaces for 4–10 days, which is aligned with the length of time 
norovirus can survive under similar conditions [36, 37]. The efficacy of a DHP 
device against airborne MS2 bacteriophage was investigated over the course of 
4 hours (Tables 1 and 4).
This trial was conducted in an aerobiology chamber with a volume of ~30 m3 to 
simulate the conditions of the DHP device’s intended use more accurately. The test 
inoculum containing a titer (~5.0 log10/mL) of MS2 bacteriophage strain 15597-B1 
was split equally and added to two separate nebulizers within the test chamber. These 
nebulizers were then activated inside the chamber for 60 minutes before the Time 
Zero sample collection occurred, using an SKC bio-sampler (500 L) equipped with 
phosphate buffered saline. The sample was then serially diluted and plated in 50% 
Tryptic Soy Agar (TSA) containing E. coli to facilitate the accurate enumeration of the 
remaining infectious MS2 bacteriophage. Subsequent samples were then collected each 
hour for the following four hours, with no DHP present, to serve as the no-treatment 
control. Once the chamber had been adequately decontaminated, the solutions 
containing the MS2 bacteriophage were again added to the nebulizers. The DHP device 
was activated after the collection of the Time Zero sample, and subsequent sample 
collections were performed identically to the control samples. All plated samples 
were then incubated for 24 hours, and the plaque-forming units (PFU) of MS2 were 
enumerated. A reduction in log10 PFU relative to the untreated control condition is 
indicative of extent of inactivation.
The Time Zero samples yielded counts of 5.84 × 104 and 5.83 × 104 PFU for the 
control and DHP-treated groups, respectively. After an hour of exposure to DHP, 
the count of plaques formed by destroyed E. coli decreased by 3.54 log10 to 1.70 × 10
1 
PFU, whereas the corresponding untreated control sample decreased by 0.83 log10 
to 8.61 × 103 PFU. Compared to the untreated control, DHP achieved a 2.71 log10 
reduction in infectious airborne MS2 bacteriophage titer after 1 hour of exposure, 
which corresponds to a 99.8% reduction (Table 4) [38].
MS2 bacteriophage titer (E. coli PFU/mL)
Time zero T = 1 hr T = 2 hr T = 3 hr T = 4 hrs
Control 5.84 × 104 8.61 × 103 2.20 × 103 5.83 × 102 7.59 × 102
DHP-Treated 5.83 × 104 1.70 × 101 ≤1.68 × 101 ≤1.58 × 101 ≤1.62 × 101
Log10 
Inactivation*
2.70 ≥2.12 ≥1.57 ≥1.67
Percent 
Reduction*
99.8% ≥99.2% ≥97.3% ≥97.9%
*Compared to control.
Table 4. 




3. Discussion and conclusions
United States Food and Drug Administration guidance [39] and the literature 
[40] suggest that small non-enveloped viruses are generally less susceptible to 
inactivation of germicidal chemicals, such as hydrogen peroxide, than enveloped 
viruses, vegetative bacteria, and vegetative fungi. The virucidal efficacies displayed 
in these three surface and air inactivation studies indicate that DHP is capable of 
reducing surface and air concentrations of both enveloped and non-enveloped 
viruses. Therefore, it can be reasonably expected that DHP will be capable of simi-
lar microbicial efficacy against vegetative bacteria and fungi as well, a hypothesis 
that is strongly supported by microbial reductions observed in the presence of DHP 
in healthcare settings [17, 27].
Within healthcare settings, the environmental microbial load is strongly associ-
ated with the risk of developing an HAI, and effective reduction of environmental 
microbial load has been shown to greatly mitigate that risk [41, 42]. It might 
seem prudent to rely on the most powerful, broad-spectrum disinfectants, such 
as full-strength VHP, caustics, or chlorine dioxide fogging, which are capable 
of inactivating pathogens to levels that approach sterile conditions. Those types 
of disinfectants, unfortunately, can only be applied intermittently. Reliance on 
intermittent methods of disinfection has repeatedly failed to demonstrate a consis-
tent and effective reduction in environmental bioburden [43]. It is apparent that, 
for strong disinfectants to achieve their full potential, these must be accompanied 
by an adjunct method of continuous microbial reduction that can mitigate levels 
of bioburden during the intervals between the periodic application of the other 
disinfectants.
In the wake of the SARS-CoV-2 pandemic which caused the COVID-19 dis-
ease, there is a unique and universal awareness of the need for effective surface 
and air hygiene methods in the commercial, educational, and residential sectors. 
This increased demand for technologies that successfully mitigate environmental 
pathogen load in sectors outside of healthcare further stresses the need for simple, 
accessible, and automated adjunct technologies to accompany intermittent micro-
bicidal application protocols and disinfectant usage. The repeated demonstration of 
the efficacy of DHP against a variety of pathogens in laboratory and field settings, 
its lack of human toxicity at the H2O2 concentrations used, and the material com-
patibility associated with DHP and its breakdown products (O2 and H2O) qualify 
the technology as a strong contender for meeting this demand.
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